Median overall survival was @ months ( IQR @-@ ) for @ patients allocated ramucirumab plus docetaxel and @ months ( @-@ ) for @ patients who received placebo plus docetaxel ( hazard ratio @ , @ % CI @-@ ; p = @ ) .